Zydus Cadila receives tentative approval from USFDA for Brivaracetam Tablets

Zydus Cadila has received tentative approval from the USFDA to market Brivaracetam Tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (US RLD: Briviact Tablets). Brivaracetam is used to treat partial-onset of seizures (epilepsy).

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.665 as compared to the previous close of Rs. 650.5. The total number of shares traded during the day was 424210 in over 9797 trades.

The stock hit an intraday high of Rs. 668.85 and intraday low of 651. The net turnover during the day was Rs. 280078523.

Source : Equity Bulls

Keywords